⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Screening for Cancer in Patients With Unprovoked VTE

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Screening for Cancer in Patients With Unprovoked VTE

Official Title: PET / CT Scan to Detect Cancer in Patients With Unprovoked Venous Thromboembolic Disease. Open Randomized Clinical Trial.

Study ID: NCT03937583

Interventions

Fludeoxyglucose 18F

Study Description

Brief Summary: Open and multicenter randomized clinical trial (1:1) comparing limited screening with extended screening with the performance of Positron emission tomography-computed tomography (PET-CT) scan in the search for neoplasms in patients with unprovoked venous thromboembolic disease at high risk of developing cancer at follow-up. Introduction: Cancer screening in patients with unprovoked venous thromboembolic disease (VTE) is controversial. In the last years, a score has been developed that selects patients at high risk of developing cancer during follow-up. Objective: To estimate the impact of an active cancer search strategy using 18-fluordesoxiglucose (FDG) PET-CT in unprovoked VTE with high-risk to develop cancer. Specific Objectives: 1) Number of neoplasms diagnosed in the screening process: 2) number of neoplasms diagnosed at an early stage, 3) impact on survival of the strategy; and 4) impact on the quality of life. Cancer will be considered from 30 days up to 12 months after the diagnosis of VTE. Scope: 20 Spanish hospitals. Design: Open-label, multicentre Randomized clinical trial (1: 1) comparing the performance of PET-CT versus limited screening for cancer. Population: Patients older than 18 years with unprovoked VTE at high risk of presenting cancer at follow-up (≥3 points in the score of Jara-Palomares et al., Chest 2017). Follow-up: 12 months after VTE. Sample: The sample size calculated is 650 patients, to obtain a power of 80%, with a level of significance of 5%, and taking into account a 10% loss of follow-up.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

Fundació Hospital de L'Esperit Sant, Santa Coloma De Gramenet, Barcelona, Spain

Hospital Universitario Virgen del Rocío, Sevilla, Seville, Spain

Hospital Clínic de Barcelona, Barcelona, , Spain

Hospital del Mar, Barcelona, , Spain

Hospital Vall d'Hebrón, Barcelona, , Spain

Consorcio Hospitalario Provincial de Castellón, Castelló, , Spain

Hospital Universitario Reina Sofía, Córdoba, , Spain

Hospital de Granollers, Granollers, , Spain

Clínica Universidad de Navarra, Madrid, , Spain

Hospital Universitario 12 de Octubre, Madrid, , Spain

Hospital Universitario Infanta Sofía, Madrid, , Spain

Hospital Universitario La Paz, Madrid, , Spain

Hospital Universitario Virgen de la Arrixaca, Murcia, , Spain

Clínica Universidad de Navarra, Pamplona, , Spain

Hospital Universitario de Valme, Sevilla, , Spain

Hospital Universitari i Politècnic La Fe, Valencia, , Spain

Contact Details

Name: Luis Jara Palomares, MD/PhD

Affiliation: Hospitales Universitarios Virgen del Rocío

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: